Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL487727 | 0.93 | THRA (0.56) | THRATHRBALOX5PTGS2LIPG | |
| Ethylene Glycol SCHEMBL3259231 | 0.93 | THRA (0.56) | THRATHRBALOX5PTGS2LIPG | |
| Ethylene Glycol SCHEMBL20582190 | 0.93 | THRA (0.56) | THRATHRBALOX5PTGS2LIPG | |
| Ethylene Glycol SCHEMBL11574529 | 0.93 | THRA (0.56) | THRATHRBALOX5PTGS2LIPG | |
| SCHEMBL36193 | 0.92 | THRA (0.49) | THRATHRBALOX5PTGS2LIPG | |
| Ethylene Glycol SCHEMBL15269369 | 0.92 | THRA (0.52) | THRATHRBALOX5PTGS2LIPG | |
| Ethylene Glycol SCHEMBL21373973 | 0.90 | THRA (0.57) | THRATHRBALOX5PTGS2LIPG | |
| Ethylene Glycol SCHEMBL11057177 | 0.90 | THRA (0.57) | THRATHRBALOX5PTGS2LIPG | |
| Ethylene Glycol SCHEMBL11667182 | 0.90 | THRA (0.57) | THRATHRBALOX5PTGS2LIPG | |
| Ethylene Glycol SCHEMBL2169345 | 0.90 | THRA (0.57) | THRATHRBALOX5PTGS2LIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1526847-A2 | PHARMACEUTICAL DOSAGE FORM COMPRISING A SULFITE COMPOUND | Pharmacia Corporation (US) | 2005-05-04 | — | — | EP | claimed |
| EP-1526845-A2 | PHARMACEUTICAL DOSAGE FORM CAPABLE OF MAINTAINING STABLE DISSOLUTION PROFILE UPON STORAGE | Pharmacia Corporation (US) | 2005-05-04 | — | — | EP | claimed |
| US-20040105883-A1 | Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage | PHARMACIA CORPORATION | 2004-06-03 | — | — | US | claimed |
| US-20040105884-A1 | Pharmaceutical dosage form comprising a sulfite compound | PHARMACIA CORPORATION | 2004-06-03 | — | — | US | claimed |
| WO-2004022032-A2 | PHARMACEUTICAL DOSAGE FORM COMPRISING A SULFITE COMPOUND | PHARMACIA CORPORATION (US) | 2004-03-18 | — | — | WO | claimed |
| WO-2004010973-A2 | PHARMACEUTICAL DOSAGE FORM CAPABLE OF MAINTAINING STABLE DISSOLUTION PROFILE UPON STORAGE | PHARMACIA CORPORATION (US) | 2004-02-05 | — | — | WO | claimed |
| US-6627108-B1 | Salicylic acid, nitrilotriacetic acid, sodium hydroxide, n,n-di-secbutylaminophenol, polyalkylene methylpolysiloxane and water; efficient elemental sulfur recovery | INSTITUT FRANCAIS DU PETROLE (FR) | 2003-09-30 | — | — | US | claimed |
| EP-1274425-A1 | RAPID-ONSET FORMULATION OF A SELECTIVE CYCLOOXIGENASE-2 INHIBITOR | Pharmacia Corporation (US) | 2003-01-15 | — | — | EP | claimed |
| US-20020107250-A1 | Rapid-onset formulation of a selective cyclooxygenase-2 inhibitor | PHARMACIA CORPORATION | 2002-08-08 | — | — | US | claimed |
| WO-2001078724-A1 | RAPID-ONSET FORMULATION OF A SELECTIVE CYCLOOXIGENASE-2 | PHARMACIA CORPORATION (US) | 2001-10-25 | — | — | WO | claimed |
| US-7950794-B2 | Solvent based inkjet ink formulation | KIIAN S.P.A. (IT) | 2011-05-31 | — | — | US | disclosed |
| EP-2323662-A1 | TREATING INFLAMMATION AND RELATED CONDITIONS WITH IRINDALONE | Ore Pharmaceuticals Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-1749070-B9 | SOLVENT BASED INKJET INK FORMULATION | KIIAN S P A (IT) | 2010-06-23 | — | — | EP | disclosed |
| US-20100069400-A1 | METHODS FOR TREATING INFLAMMATION AND RELATED CONDITIONS | ORE PHARMACEUTICALS INC. (US) | 2010-03-18 | — | — | US | disclosed |
| WO-2010006231-A1 | TREATING INFLAMMATION AND RELATED CONDITIONS WITH IRINDALONE | ORE PHARMACEUTICALS INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2001078724-A1 | RAPID-ONSET FORMULATION OF A SELECTIVE CYCLOOXIGENASE-2 | PHARMACIA CORPORATION (US) | 2001-10-25 | — | — | WO | disclosed |
| US-6210454-B1 | A GAS CONTAINING SULFUR DIOXIDE AND HYDROGEN SULFIDE IS CONTACTED WITH AN ORGANIC SOLVENT CONTAINING A CATALYST IN A GAS-LIQUID REACTOR-CONTACTOR AT A PREFERED TEMPERATURE, ALL THE SULFUR RECOVERD FREE OF SULFUR DIOXIDE/ HYDROGEN SULFIDE | INSTITUT FRANCAIS DU PETROLE (FR) | 2001-04-03 | — | — | US | disclosed |
| US-5951961-A | Process for treating a gas containing hydrogen sulphide and sulphur dioxide, comprising a step for eliminating sulphur by cooling a gaseous effluent | INSTITUT FRANCAIS DU PETROLE (FR) | 1999-09-14 | — | — | US | disclosed |
| US-5935547-A | CONTACTING HYDROGEN SULFIDE WITH SULFUR DIOXIDE INTO A SOLVENT AND RECOVERING A GASEOUS EFFLUENT CONTAINING WATER AND SULFUR VAPORS, INTRODUCING EFFLUENT TO RECYCLED SOLVENT DEPLETED IN SULFUR, COOLING TO SEPARATE SULFUR CRYSTALS | INSTITUT FRANÇAIS DU PETROLE (FR) | 1999-08-10 | — | — | US | disclosed |
| EP-0844292-A1 | Composition and use thereof in conversion of a gas containing hydrogen sulfide and sulfur dioxide to sulfur | INSTITUT FRANCAIS DU PETROLE (FR) | 1998-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040105884-A1 | Pharmaceutical dosage form comprising a sulfite compound | PTGS2, PTGES2, PTGS1 | THRA 4729/4885THRB 4769/4885ALOX5 58/4885 |
| US-20020107250-A1 | Rapid-onset formulation of a selective cyclooxygenase-2 inhibitor | PTGER2, PTGES2, PTGER1 | THRA 4278/4885THRB 4580/4885ALOX5 30/4885 |
| US-20040105883-A1 | Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage | PTGS2, PTGES2, PTGER2 | THRA 4615/4885THRB 4762/4885ALOX5 31/4885 |
| US-20100069400-A1 | METHODS FOR TREATING INFLAMMATION AND RELATED CONDITIONS | IL17A, CCR10, CXCL8 | THRA 2627/4885THRB 2585/4885ALOX5 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.